SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-060044
Filing Date
2024-05-15
Accepted
2024-05-15 07:53:10
Documents
101
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q atai-20240331.htm   iXBRL 10-Q 2869857
2 EX-10.2 atai-ex10_2.htm EX-10.2 92199
3 EX-31.1 atai-ex31_1.htm EX-31.1 14100
4 EX-31.2 atai-ex31_2.htm EX-31.2 15392
5 EX-32.1 atai-ex32_1.htm EX-32.1 8805
6 EX-32.2 atai-ex32_2.htm EX-32.2 8657
7 GRAPHIC img106862227_0.jpg GRAPHIC 316220
  Complete submission text file 0000950170-24-060044.txt   16758411

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT atai-20240331.xsd EX-101.SCH 3267729
105 EXTRACTED XBRL INSTANCE DOCUMENT atai-20240331_htm.xml XML 2800453
Mailing Address 524 BROADWAY NEW YORK NY 10013
Business Address WALLSTRASSE 16 BERLIN 2M 10179 (617)-699-5876
ATAI Life Sciences N.V. (Filer) CIK: 0001840904 (see all company filings)

IRS No.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40493 | Film No.: 24947208
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)